Form 4: Compass Therapeutics CFO Awarded Stock Options and Restricted Stock Units

Compass Therapeutics' CFO, Barry Shin, received 400,000 stock options and 400,000 restricted stock units on December 9, 2024, subject to vesting conditions.

Summary

• Compass Therapeutics granted Barry Shin, the company's CFO, 400,000 stock options and 400,000 restricted stock units (RSUs) on December 9, 2024.
• The stock options have an exercise price of $1.65 per share.
• The RSUs represent a contingent right to receive one share of common stock each.
• Both the options and RSUs are subject to service-based vesting conditions.
• The RSUs vest in four equal annual installments, with the first vesting on December 9, 2025.
• The options vest 25% on December 9, 2025, and the remaining portion vests over 36 substantially equal monthly installments starting January 9, 2026.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Compass Therapeutics' stock price.
• If the CFO leaves the company before the vesting dates, they may forfeit some or all of the unvested options and RSUs.

Future Outlook

The vesting schedule of the stock options and RSUs is designed to incentivize the CFO's long-term performance and commitment to the company.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry, often with similar vesting schedules.
• Companies like Amgen, Gilead, and Biogen also use equity-based compensation to align executive interests with shareholder value.
• The vesting schedule of four years for RSUs and a mix of cliff and monthly vesting for options is typical in the industry.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively as it incentivizes the CFO to improve company performance.
• The CFO is incentivized to remain with the company and contribute to its long-term success.

Key Dates

Keywords

stock options, restricted stock units, RSU, vesting, executive compensation, CFO, Compass Therapeutics, CMPX